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Thio-conjugation of substituted benzofurazans to
peptides: molecular sieves catalyze nucleophilic
attack on unsaturated fused rings†
Valentina Verdoliva,a Giuseppe Digilio,b
Michele Saviano c and Stefania De Luca *a
Bioconjugates of 2,1,3-benzoxadiazole (benzofurazan) and its derivatives have attracted considerable
interest due to their biological activities and applications as fluorescent tags. A high-yield, chemoselective,
and mild procedure for the S-alkylation of cysteine containing peptides by benzofurazan halogenides is
reported. The key feature of this procedure is the use of activated molecular sieves (MS) to catalyze thiol
activation for nucleophilic substitution under very mild conditions (room temperature and no need for
added bases). To the best of our knowledge, this is the first report about thiol nucleophilic substitution
performed on unsaturated and annelated systems catalyzed by activated molecular sieves. Reaction yields
were remarkable even with benzofurazans having weakly activating groups or no activating groups at all.
The potential of the new methodology was explored by synthesizing fluorescent, hydrophilic
benzofurazan/peptide conjugates, also with peptides containing unprotected lysine residues.
Introduction
In the field of chemical biology, there is constantly increasing
interest in developing bioconjugation strategies aimed at the
selective modification of natural or non-natural amino acids
to introduce exogenous moieties (such as drugs or tracers)
into peptides.1,2 Such modifications could allow the
manipulation of peptides or peptidomimetics with
therapeutic potential and the introduction of probes useful
for investigating biomolecular interactions. Among the 20
proteinogenic amino acids, cysteine represents one of the
most viable targets for conjugation, due to its low natural
abundance and to its strong nucleophilicity under slightly
basic conditions (pH < 9).3–5
The introduction of 2,1,3-benzoxadiazole moieties
(benzofurazan) into peptide structures has shown useful
application in biological and medicinal chemistry. Suitably
substituted benzofurazans are commonly employed as
fluorogenic reagents6–9 to label biomolecules and have also
found clinical application as antibacterial and antiparasitic,
as well as antiviral and antitumor agents.10–12
To date, several fluorescent 4,7-substituted benzofurazan
derivatives have been investigated and employed as fluorogenic
labels.13,14 Amongst them, 4-chloro-7-nitrobenzofurazan (a-Cl)
is largely used as a fluorescent tag to label proteins and
peptides. Indeed, its high reactivity to nucleophilic attack
makes the conjugation chemistry easy to perform under
slightly basic conditions.15–18 Other fluorescent/fluorogenic
tags employed for biomolecule labelling rely on ionic
benzofurazan derivatives. 4-Chloro-7-sulfobenzofurazan (b-Cl)
and 4-fluoro-7-sulfobenzofurazan (b-F) can react specifically
with a thiol group and are particularly suitable for analytical
purposes. The advantage of such ionic benzofurazans is that
they do not impart any hydrophobic character to the
fluorescent adducts, thus enhancing the reliability of the
assay.13,14 As the sulfonate group induces a weaker ring
activating effect compared to the nitro group, the conjugation
reaction of 7-sulfobenzofurazan halogenides (b-X) still requires
basic pH (always >9) and a temperature around 60 degrees.
These conditions could not be fully compliant with peptide
modification. Therefore, a new synthetic protocol employing
milder conditions for benzofurazan conjugation was explored.
An efficient and selective S-alkylation method to introduce
modifications on a cysteine residue within peptide sequences
was developed by our group. The key feature of this method is
the use of activated molecular sieves (MS) as the catalyst to
activate the thiol function for nucleophilic substitution under
very mild conditions (room temperature and no need for any
bases). It is worth remembering that cationic zeolites, such as
alkaline-LTA, have been proven to be naturally endowed with
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mild basic properties, which is a great advantage compared to
the basic strength of the commonly employed organic bases.19
By such a method, a variety of chemical functions were
successfully introduced into polypeptides, including
fluorophores, PEG units and lipid moieties that represent
protein post-translational modifications. S-linked glycopeptides
and lantipeptides were also successfully obtained.3,20–26
Here we applied our method to selectively conjugate either
substituted or unsubstituted benzofurazans to cysteine
containing peptides.
Results and discussion
We started our investigation by reacting model peptide 1,
bearing a cysteine residue at its N-terminus and no other
nucleophiles, with a-Cl (4-chloro-7-nitrobenzofurazan) and b-X
(4-chloro-/4-fluoro-7-sulfobenzofurazan) in the presence of
activated 4 Å MS as the catalyst. MS were activated by heating
at 280 °C for 4 h under vacuum, and the coupling reaction
was carried out in DMF under an argon atmosphere. The
benzofurazan derivative was reacted in 1.2 equiv. excess and
the mixture was kept under stirring for 12 hours at room
temperature. The yield of compound 1a was excellent (90%).
That of compound 1b was very high as well, either by using
b-Cl or b-F (85%, see Scheme 1).
These results prompted us to continue with a deeper
investigation to assess whether the nucleophilicity of the
cysteine was affected by its relative position within the
peptide sequence. Moreover, two potentially sensitive
nucleophilic amino acids (Trp and His) were inserted into
the sequence in close proximity to the cysteine residue.
Model peptide 2 was conjugated with a-Cl and b-X (X = Cl, F).
To better assess the catalytic efficiency of molecular sieves
with respect to the standard chemistry for thiol activation,
the thio-conjugation was performed either in the presence of
DIPEA (strategy A) or in the presence of activated MS (strategy
B), and the yields of the two synthetic strategies were
compared. As shown in Scheme 2, the standard conditions
(strategy A: 3 equiv. DIPEA, rt and 12 h) provided compound
2a in quite high yield, as expected, while they provided
compound 2b in low or very low yield (20% and 5% by using
b-Cl or b-F, respectively). The yield was assessed by the ratio
between the HPLC peak area of the desired final product and
the total area relative to peptides (including the unreacted
peptide, the product, and by-products).
The same conjugation reactions (Scheme 2) performed
according to strategy B gave compound 2a with an enhanced
yield (85%). Enhanced yields were also achieved for
compound 2b (50%), by using both b-Cl or b-F as the
coupling reagent (Scheme 2). This represents a huge
improvement compared to the yields obtained by following
strategy A. Compared to the yield (85%) obtained for
compound 1b, we observed a lower yield (50%) for compound
2b, even though the same benzofurazan halogenides b-X (X =
Cl, F) were used as reagents. Likely, the more hindered
position of the cysteine residue in peptide 2 limits the final
functionalization yield.
A detailed structural characterization of the reaction
products was carried out by NMR to confirm that
benzofurazan conjugation occurred at the cysteine sulfur
atom and not at the potentially competing nucleophilic
nitrogen atoms of tryptophan or histidine side chains. First,
full proton resonance assignment was achieved by means of
the sequence-specific method based on the iterative analysis
of 2D-TOCSY and 2D-ROESY NMR spectra. Then, the 2D-
ROESY NMR spectra were analyzed further for short
distances involving the benzofurazan ring protons and
neighboring amino acid side chain protons (representative
2D-NMR spectra for compound 2b are shown in Fig. 1; see
also the ESI†). The formation of the S-conjugation product
was unambiguously confirmed by the detection of intense
ROE peaks (i.e. short interproton distances) between the
cysteine Hα/Hβ protons and the benzofurazan H5 ring proton.
No ROE signals between benzofurazan ring protons and side
chain protons of tryptophan and histidine were detected.
Next, the accessibility to the thiol nucleophilic attack of
benzofurazans bearing a halogen substituent at either
position 4 or 5 was checked. The S-conjugation of peptide 1
Scheme 1 Incorporation of halogen-sulfo/nitro-benzofurazans in
peptide 1.
Scheme 2 Incorporation of halogen-sulfo/nitro-benzofurazans in
peptide 2.
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and peptide 2 was performed with the substrates shown in
Schemes 3 and 4. These benzofurazan substrates lack any
electron-withdrawing group activating the substrate. For
comparison, the same reactions were repeated in the
presence of DIPEA as the base (strategy A: 3 equiv. DIPEA, rt
and 12 h).
The yields for all the conjugates obtained by following the
DIPEA protocol (strategy A) were poor or negligible.
Meanwhile, the MS activation protocol (strategy B) provided
the final products with yields ranging from 10% (2c, X = Cl)
to 65% (1c, X = F) (Scheme 3). The NMR analysis confirmed
that S-conjugation occurred at the expected position on the
benzofurazan ring (i.e. at position 4 for 1c/2c and at position
5 for 1d/2d). This was confirmed by the detection of the
expected pattern of ROE contacts between cysteine Hα/Hβ
protons and the benzofurazan H5 proton (in compounds 1c
and 2c), or the benzofurazan H4 proton (in compounds 1d
and 2d). In addition, 2D 1H,13C HMBC NMR spectra showed
the expected heteronuclear 3JHC correlation between Cys Hβ
and the quaternary C4 carbon in compound 2c, or that
between Cys Hβ and the quaternary C5 carbon for compound
2d (see the ESI†).
Concerning the 4-halogenobenzofurazans (c-X), the fluoro
group was more reactive than the chloro group toward the
sulfhydryl attack, for both peptides (Scheme 3). This trend is
in agreement with the hypothesized mechanism of the
nucleophilic substitution of halogen-benzofurazans, which
proceeds through a two-step mechanism of SNAr type, even
though they are not aromatic substrates. It is worth noting
that the same trend was not so clearly observed for the
7-sulfo-benzofurazan rings, likely because the ring activating
effect of the sulfonic group flattens the effect of the leaving
halogen, especially when the products are obtained in high
yields (Scheme 1).
Meanwhile, the reactivity order involving the leaving group
for the 5-halogenobenzofurazans was in the order Br > Cl, i.e.
the opposite of that typically observed for nucleophilic
substitution on activated benzofurazan rings. In fact,
halogen-benzofurazans have to be treated as halogen-
activated unsaturated derivatives where the electron-
withdrawing furazan group exerts an activating effect. In
other words, dealing with the reaction mechanism, there is
evidence that in some cases the order of halogen substituted
benzofurazans followed that expected for the SNAr
mechanism (F > Cl ∼ Br), in other cases it did not. The
reaction mechanism is still unclear, and it deserves further
investigations. An additional consideration concerns the
higher yield of the conjugates obtained from benzofurazans
substituted at position 5 (d-X) (Scheme 4). This could be
explained by the better accessibility of position 5 to the
nucleophile (d-X) compared to that of position 4 (c-X), which
is peri within the annelated system (see Table 1).27
As the conjugates obtained from 5-bromobenzofurazan (d-
Br) were collected in high yields (Scheme 4), a further study
aimed at assessing the chemoselectivity for cysteine thiol was
carried out on peptide sequences containing either Trp, Met,
His, Thr, or Lys as potential nucleophile competitors
(Scheme 5, panel A).
All sequences proved to react selectively with
5-bromobenzofurazan (d-Br) through the cysteine thiol, as
confirmed by NMR analysis (see the ESI†), and all peptides
provided high conjugation yields. Remarkably, a very high
Fig. 1 Overlay between the 2D-TOCSY (black peaks) and the 2D-
ROESY (red peaks) NMR spectra of compound 2b (600 MHz, DMSO-d6,
298 K) showing the expansion over the fingerprint region. 2D-TOCSY
strips with amino acid assignment are shown. ROE cross-peaks
connecting the benzofurazan ring H5 proton and cysteine Hα and Hβ
protons are indicated. 2D NMR spectra with full proton resonance
assignments for all compounds considered are reported in the ESI.†
Scheme 3 Incorporation of 4-halogen-benzofurazan in peptide sequences.
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chemoselectivity was also found when the competitor was the
amino group of lysine that, amongst the side chain
functional groups that are typically found in natural peptides,
is by far the most potent competitor of the cysteine sulfhydryl
group for nucleophilic attack. As a matter of fact, the
synthesis of compound 7d (Scheme 5, panel A) gave the
mono-S-alkylated peptide in high yield (80%), and no di-
alkylation product (i.e. both on cysteine and lysine) was
found at all by means of mass spectrometry.
These results prompted us to assess whether such a thiol-
specificity was maintained also by 4-chloro-7-
sulfobenzofurazan b-Cl (also known as Sbf), whose
chemoselectivity in basic aqueous media under heating has
already been established.13 As depicted in
Scheme 5 (panel B), the reaction of b-Cl with peptide 7
(containing both cysteine and lysine) gave the mono-S-
alkylated product 7b with an 85% yield.
The fluorescence emission spectrum of the purified
product was characterized by an emission peak at 520 nm
(excitation at 380 nm, see Fig. 2), that is typical and fully
consistent with a Sbf-thiol derivative. Again, no di-alkylated
or N-alkylated products were found, either by HPLC-MS or
fluorescence spectroscopy (fluorescence emission spectra of
Sbf-amine derivatives should give a typical emission peak at
590 nm when excited at 411 nm, which was not detected).
Experimental section
Materials and methods
Fmoc protected amino acids, Rink amide MBHA resin,
N-hydroxybenzotriazole (HOBT) and benzotriazol-1-yl-oxy-tris-
pyrrolidino-phosphonium (PyBOP) were purchased from
Calbiochem-Novabiochem (Laufelfingen, Switzerland);
piperidine and diisopropylethylamine (DIPEA) were
purchased from Fluka (Milwaukee, WI); all solvents were
purchased from Aldrich (St Louis, MI) or Fluka (Milwaukee,
WI) and were used without further purification, unless
otherwise stated. Molecular sieves, type 4 Å (beads, diameter
1.6 mm) were purchased from Aldrich and activated by
heating at 280 °C for 4 h under vacuum. The benzofurazans
[(4-chloro-benzofurazan, 4-chloro-7-sulfobenzofurazan
ammonium salt, 4-chloro-7-nitrobenzofurazan), (4-fluoro-
benzofurazan, 5-chloro-benzofurazan, 5-bromo-benzofurazan,
Scheme 4 Incorporation of 5-halogen-benzofurazan in peptide sequences.
Scheme 5 Chemoselectivity of benzofurazans for cysteine in peptides
containing potentially competing nucleophilic groups.
Table 1 Efficiency of S-conjugation to introduce benzofurazan
substituents into peptides
Entrya Peptide Yield (%) DIPEA Yield (%) MS
1a AcC(a)GVANH2 — Cl: 90
1b AcC(b)GVANH2 — X = Cl: 85
X = F: 85
1c AcC(c)GVANH2 ny X = F: 65
X = Cl: 50
1d AcC(d)GVANH2 ny X = Br: 85
X = Cl: 30
2a AcGWC(a)HVANH2 Cl: 60 Cl: 85
2b AcGWC(b)HVANH2 X = Cl: 20 X = Cl: 50
X = F: 5 X = F: 50
2c AcGWC(c)HVANH2 X = F: 5 X = F: 50
X = Cl: ny X = Cl: 10
2d AcGWC(d)HVANH2 X = Br: ny X = Br: 40
X = Cl: ny X = Cl: 20
3d AcC(d)GMVANH2 — Br: 90
4d AcC(d)GWVANH2 — Br: 50
5d AcC(d)GTVANH2 — Br: 75
6d AcC(d)GVHANH2 — Br: 60
7d AcC(d)GKVANH2 — X = Br: 80
7b AcC(b)GKVANH2 — X = Cl: 85
a Twelve hours reaction time at room temperature; ny: negligible yield.
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4-fluoro-7-sulfobenzofurazan ammonium salt)] were
purchased from Sigma Aldrich and from Santa Cruz
Biotechnology (Heidelberg).
For all the RP-HPLC procedures the system solvent used
was: H2O 0.1% TFA (A) and CH3CN 0.1% TFA (B) and
detection was performed at 210 nm and 280 nm. Analytical
RP-HPLC runs were carried out on a HP Agilent Series 1100
apparatus using a Phenomenex (Torrance, California) Kinetex
column (5 μm C18 100 A – 60 × 4.60 m) with a flow rate of
1.0 mLmin−1and a linear gradient starting from 5% to 70% B
in 10 min; preparative RP-HPLC was carried out on a HP
Agilent Series 1200 apparatus using a Phenomenex (Torrance,
California) Gemini column (5 μm NX-C18 110 Å – 150 × 21.2
mm, AXIA™) with a flow rate of 15 mLmin−1 and a linear
gradient starting from 5% to 70% B in 20 min.
LC-ESI-TOF-MS analyses were performed with an Agilent
1290 Infinity LC system coupled to an Agilent 6230 TOF LC/MS
system (Agilent Technologies, CernuscoSulNaviglio, Italy). The
system solvent used was: H2O 0.05% TFA (A) and CH3CN 0.05%
TFA (B); Phenomenex (Torrance, California) Jupiter column (3
μm C18 300 Å – 150 × 2.0 mm); linear gradient starting from
5% to 70% B in 20 min and detection at 210 nm and 280 nm.
NMR spectra were acquired with a Bruker Avance
spectrometer operating at 14 T (corresponding to a proton
Larmor frequency of 600 MHz), equipped with an inverse
Z-gradient 5 mm BBI probe. The temperature was set to 298.0
K, and controlled within ±0.1 K by means of a BTO2000 VTU
system. Samples were dissolved in 600 μL of DMSO-d6 (99.9
atom%). The residual solvent resonance at 2.54 ppm was
used as a secondary reference for chemical shift calibration.
Resonance assignment was based on the analysis of
homonuclear 2D-TOCSY and 2D-ROESY NMR spectra. The
2D-TOCSY spectra were acquired with the Bruker mlevphpr
pulse program (homonuclear Hartman–Hahn transfer by
means of the MLEV17 sequence28) in the phase-sensitive
mode according to the States-TPPI scheme. Typical
acquisition parameters included: 2 s relaxation delay, 32–64
scans, 16 dummy scans, 25 Hz bandwidth for the water
suppression presaturation pulse (if required), 2048 × 256–400
data points, 13 ppm spectral width (in F2 and F1), and 100
ms mixing time. Data were treated with squared cosine
window functions (both along F2 and F1) prior to complex FT.
The 2D-ROESY spectra were acquired with the Bruker
roesyphpr.2 pulse program in the phase-sensitive mode by
the States TPPI scheme.29 Typical acquisition and processing
parameters were similar to those for the 2D-TOCSY spectra,
but with a mixing time of 300 ms at 2.5 kHz spin-lock field
strength, and 64 scans. 2D 1H,13C 2D HSQC NMR spectra
were acquired by means of the Bruker hsqcetgp pulse
program in the phase sensitive mode using Echo/Antiecho-
TPPI gradient selection and with decoupling during
acquisition. Acquisition parameters included 1024 × 128 data
points, 14 ppm (1H) and 165 ppm (13C) spectral window, and
16–64 scans. 2D 1H,13C 2D HMBC NMR spectra to detect long
range 1H/13C couplings were acquired by means of the Bruker
hmbcgplpndqf pulse program in the phase-insensitive mode
with a low-pass J-filter to suppress one-bond correlations and
no decoupling during acquisition. Acquisition parameters
included 2048 × 128 data points, 14 ppm (1H) and 220 ppm
(13C) spectral window, 32–128 scans, and 60 ms delay for the
evolution of long range couplings. The spectra were
processed using the Bruker Topspin 4 software package.
Sequence specific assignment was carried out using the
Computer Aided Resonance Assignment software package
(CARA: R.L.J Keller “The Computer Aided Resonance
Assignment”, 2004 CANTINA Verlag, Goldau, Switzerland).
Fluorescence spectra were recorded at room temperature
on a Varian Cary Eclipse spectrofluorimeter, equipped with a
1.0 cm quartz cell, with an excitation wavelength of 380 nm
and an emission range of 400–600 nm. Equal excitation and
emission bandwidths were used throughout experiments,
with a recording speed of 120 nm min−1 and automatic
selection of the time constant.
Peptide synthesis
Peptide synthesis was carried out manually by a solid-phase
method using the standard Fmoc-protecting group strategy.
Appropriate Fmoc-amino acid derivatives [Fmoc-Ala-OH, Fmoc-
Val-OH, Fmoc-Gly-OH, Fmoc-CysĲTrt)-OH, Fmoc-Met-OH,
Fmoc-HisĲTrt)-OH, Fmoc-TrpĲBoc)-OH, Fmoc-thrĲtBu)-OH,
Fmoc-LysĲBoc)OH] were employed and a Rink amide MBHA
resin (0.7 mmol g−1 substitution; 50 μmol scale) was used as a
solid support, as it releases peptides amidated at the
C-terminus upon acid treatment. All Fmoc-amino acids were
activated by an in situ PyBop/HOBt//DIPEA activation
procedure. Amino acid coupling steps were monitored by the
Kaiser test after 60 min coupling cycles. Fmoc-deprotection was
performed with 20% piperidine in DMF for 5 + 10 min. The
peptide N-terminus was acetylated by treatment with a mixture
of acetic anhydride (4.7%) and pyridine (4%) in DMF for 10
min. The cleavage from the solid support and the simultaneous
deprotection of all side chains were performed by suspending
the fully protected compound-resins in TFA/H2O/TIS (97 : 2 : 1)
for 3 h. The peptides were isolated by precipitation in cold
diethyl ether and centrifuged to form a pellet.
Fig. 2 Fluorescence emission spectrum (λex = 380 nm) of
sulfobenzofurazan derivative 7b in water (the inset shows the
spectrum of b-Cl).
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General procedure for post-synthetic peptide S-alkylation
Each solution of acetylated peptide in DMF (5 mg mL−1) was
kept under an argon atmosphere for 5 min. Then, the solution
was transferred, using a syringe, in a 10 mL round-bottom flask
covered with a rubber top and containing 4 Å molecular sieves
(3–3.5 g), previously activated at 280 C° for 4 h under vacuum
(10−4 mbar). After a few minutes, the benzofurazans (1.2 equiv.)
were added to the reaction mixture that was stirred at room
temperature for 12 h. The mixture was centrifuged to eliminate
the sieves and the supernatant was concentrated under
vacuum. RP-HPLC and mass spectrometry analyses were
performed on the obtained crude and each recovered final
product fully characterized by NMR spectroscopy.
Compound 1a strategy B – AcCysĲa)GlyValAlaNH2. 6.9 mg
of peptide 1 was reacted with 4.23 mg of 4-chloro-7-
nitrobenzofurazan (a) in the presence of activated molecular
sieves and under an argon atmosphere. The reaction mixture
was stirred at room temperature for 12 h.
Yield (1a) after RP-HPLC purification: 50% (3.4 mg);
preparative HPLC tR = 17.844 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C21H29N8O8S
+ 553.1824, found 553.1920
([M + H]+). Yellow solid.
Compound 1a 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.61 (d, 1H), (8.56 t, 1H), 8.54 (d, 1H), 8.02 (d, 1H), 7.86 (d,
1H), 7.67 (d, 1H), 7.23 (s, 1H), 6.99 (s, 1H), 4.76 (dt, 1H),
4.23–4.21 (m, o, 2H), 3.87 (dd, 1H), 3.79–3.76 (m, o, 2H), 3.53
(dd, 1H), 2.03 (m, 1H), 1.91 (s, 3H), 1.25 (d, 3H), 0.90 (d, 3H),
0.86 (d, 3H).
Compound 1b (X: Cl) strategy B – AcCysĲb)GlyValAlaNH2.
6.3 mg of peptide 1 was reacted with 4.83 mg of 4-chloro-7-
sulfobenzofurazan (b-Cl) in the presence of activated
molecular sieves and under an argon atmosphere. The
reaction mixture was stirred at room temperature for 12 h.
Yield (1b) after RP-HPLC purification: 22% (1.3 mg);
preparative HPLC tR = 12.728 min (close to the tR of the
substrate employed b-Cl); HRMS (ESI-TOF) m/z: [M + H]+
calculated for C21H30N7O9S2
+ 588.1541, found 588.1545.
Yellow solid.
Compound 1b (X: F) strategy B – AcCysĲb)GlyValAlaNH2.
4.0 mg of peptide 1 was reacted with 2.90 mg of 4-fluoro-7-
sulfobenzofurazan (b-F) in the presence of activated
molecular sieves and under an argon atmosphere. The
reaction mixture was stirred at room temperature for 12 h.
Yield (1b) after RP-HPLC purification: 22% (1.8 mg);
preparative HPLC tR = 13.043 min (co-eluted with the substrate
employed b-F); HRMS (ESI-TOF) m/z: [M + H]+ calculated for
C21H30N7O9S2
+ 588.1541, found 588.1514. Yellow solid.
Compound 1b 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.53 (t, 1H), 8.42 (d, 1H), 8.00 (d, 1H), 7.78 (d, 1H), 7.67 (d,
1H), 7.47 (d, 1H), 7.21 (s, 1H), 6.98 (s, 1H), 4.63 (dt, 1H),
4.23–4.21 (m, o, 2H), 3.83 (dd, 1H), 3.74 (dd, 1H), 3.61 (dd,
1H), 3.38 (m, overlapping with the water residual signal), 2.02
(m, 1H), 1.88 (s, 3H), 1.24 (d, 3H), 0.89 (d, 3H), 0.85 (d, 3H).
Compound 1c (X: F) strategy B – AcCysĲc)GlyValAlaNH2.
6.4 mg of peptide 1 was reacted with 2.73 mg of
4-fluorobenzofurazan (c-F) in the presence of activated
molecular sieves and under an argon atmosphere. The
reaction mixture was stirred at room temperature for 12 h.
Yield (2c) after RP-HPLC purification: 32% (2.0 mg);
preparative HPLC tR = 17.068 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C21H30N7O6S
+ 508.1973, found 508.1949.
White solid.
Compound 1c (X: Cl) strategy B – AcCysĲc)GlyValAlaNH2.
7.6 mg of peptide 1 was reacted with 3.61 mg of 4-chloro-
benzofurazan (c-Cl) in the presence of activated molecular
sieves and under an argon atmosphere. The reaction mixture
was stirred at room temperature for 12 h.
Yield (1c) after RP-HPLC purification: 28% (2.1 mg);
preparative HPLC tR = 17.123 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C21H30N7O6S
+ 508.1973, found 508.1949.
White solid.
Compound 1c 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.49 (t, 1H), 8.43 (d, 1H), 8.01 (d, 1H), 7.87 (d, 1H), 7.80 (d,
1H), 7.58–7.55 (AB system, 2H), 7.22 (s, 1H), 6.99 (s, 1H), 4.63
(dt, 1H), 4.23–4.20 (m, o, 2H), 3.83 (dd, 1H), 3.74 (dd, 1H),
3.61 (dd, 1H), 3.36 (dd, overlapping with the water residual
signal), 2.03 (m, 1H), 1.88 (s, 3H), 1.24 (d, 3H), 0.89 (d, 3H),
0.85 (d, 3H).
13C-NMR δ, ppm, (from HSQC/HMBC, 150 MHz, DMSO-
d6, 298 K): 174.8, 171.0, 170.7, 170.5, 169.3, 149.7, 149.3,
133.7, 128.3, 126.7, 112.8, 58.4, 52.3, 48.8, 43.0, 33.8, 31.2,
23.3, 19.8, 18.8, 18.6.
Compound 1d (X: Br) strategy B – AcCysĲd)GlyValAlaNH2.
6.2 mg of peptide 1 was reacted with 3.83 mg of
5-bromobenzofurazan (d-Br) in the presence of activated
molecular sieves and under an argon atmosphere. The
reaction mixture was stirred at room temperature for 12 h.
Yield (1d) after RP-HPLC purification: 48% (3.0 mg);
preparative HPLC tR = 17.181 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C21H30N7O6S
+ 508.1973, found 508.1955.
White solid.
Compound 1d (X: Cl) strategy B – AcCysĲd)GlyValAlaNH2.
6.4 mg of peptide 1 was reacted with 3.04 mg of
5-chlorobenzofurazan (d-Cl) in the presence of activated
molecular sieves and under an argon atmosphere. The
reaction mixture was stirred at room temperature for 12 h.
Yield (1d) after RP-HPLC purification: 18% (1.1 mg);
preparative HPLC tR = 17.190 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C21H30N7O6S
+ 508.1973, found 508.2059.
White solid.
Compound 1d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.58 (t, 1H), 8.46 (d, 1H) 8.02 (d, 1H), 8.00 (d, 1H), 7.89 (d, 1H),
7.81 (d, 1H), 7.48 (d, H1), 7.22 (s, 1H), 6.99 (s, 1H), 4.68 (dt,
1H), 4.24–4.22 (m,o, 2H), 3.86 (dd, 1H), 3.77 (dd, 1H), 3.52 (dd,
1H), 3.33 (dd, overlapping with the water residual signal), 2.03
(m, 1H), 1.91 (s, 3H), 1.25 (d, 3H), 0.90 (d, 3H), 0.86 (d, 3H).
13C-NMR δ, ppm, (from HSQC/HMBC, 150 MHz, DMSO-d6,
298 K): 174.8, 171.1, 171.0, 170.8, 170.5, 169.6, 149.9, 148.6,
144.1, 136.9, 134.2, 127.7, 124.3, 121.4, 119.1, 118.7, 116.3,
111.8, 110.3, 107.9, 58.4, 54.0, 51.8, 48.7, 42.7, 33.7, 31.1, 28.3,
23.2, 19.6, 18.9, 18.8.
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Compound 2a strategy A – AcGlyTrpCysĲa)HisValAlaNH2.
4.7 mg of peptide 2 was reacted with 1.58 mg of 4-chloro-7-
nitrobenzofurazan (a) in the presence of 3.35 μL of DIPEA (3
equiv.). The reaction mixture was stirred at room temperature
for 12 h.
Yield (2a) after RP-HPLC purification: 30% (1.4 mg);
preparative HPLC tR = 18.069 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H46N13O10S
+ 876.3206, found 876.3182.
Yellow solid.
Compound 2a strategy B – AcGlyTrpCysĲa)HisValAlaNH2.
6.5 mg of peptide 2 was reacted with 2.20 mg of 4-chloro-7-
nitrobenzofurazan (a) in the presence of activated molecular
sieves and under an argon atmosphere. The reaction mixture
was stirred at room temperature for 12 h.
Yield (2a) after RP-HPLC purification: 47% (3.0 mg);
preparative HPLC tR = 18.302 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H46N13O10S
+ 876.3206, found 876.3658.
Yellow solid.
Compound 2a 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
10.85 (d, H1), 8.97 (br), 8.64 (m, o, 1H), 8.62 (m, o, 1H), 8.47
(d, 1H), 8.17–8.10 (m, o, 3H), 7.90 (d, 1H), 7.60 (d, 1H), 7.58
(d, 1H), 7.37 (br), 7.33 (d, 1H), 7.27 (br, 1H), 7.16 (d, 1H),
7.06 (t, 1H), 7.01 (s, 1H), 6.97(t, 1H), 4.71–4.70 (m,o, 2H), 4.57
(m, 1H), 4.24 (m, 1H), 4.18 (m, 1H), 3.76 (dd, o, 1H), 3.70
(dd, o, 1H), 3.60 (dd, o, 1H), 3.58 (dd, o, 1H), 3.17 (dd, 1H),
3.10 (br, 1H), 3.03 (br, 1H), 2.97 (dd, 1H), 2.05 (m, 1H), 1.84
(s, 3H), 1.25 (d, 3H), 0.89 (d, 3H), 0.86 (d, 3H).
Compound 2b (X: Cl) strategy A – AcGlyTrpCysĲb)-
HisValAlaNH2. 5.8 mg of peptide 2 was reacted with 2.51 mg
of 4-chloro-7sulfobenzofurazan (b-Cl) in the presence of 3.35
μL of DIPEA (3 equiv.). The reaction mixture was stirred at
room temperature for 12 h.
Yield (2b) after RP-HPLC purification: 12% (0.7 mg);
preparative HPLC tR = 15.329 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O11S2
+ 911.2923, found 911.2884.
Yellow solid.
Compound 2b (X: Cl) strategy B – AcGlyTrpCysĲb)-
HisValAlaNH2. 5.8 mg of peptide 2 was reacted with 2.51 mg of
4-chloro-7sulfobenzofurazan (b-Cl) in the presence of activated
molecular sieves and under an argon atmosphere. The reaction
mixture was stirred at room temperature for 12 h.
Yield (2b) after RP-HPLC purification: 26% (1.5 mg);
preparative HPLC tR = 15.388 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O11S2
+ 911.2923, found 911.3159.
Yellow solid.
Compound 2b (X: F) strategy A – AcGlyTrpCysĲb)-
HisValAlaNH2. 4.7 mg of peptide 2 was reacted with 1.86 mg
of 4-fluoro-7-sulfobenzofurazan (b-F) in the presence of 3.35
μL of DIPEA (3 equiv.). The reaction mixture was stirred at
room temperature for 12 h.
Yield (2b) after RP-HPLC purification: 0.5%; preparative
HPLC tR = 21.112 min; HRMS (ESI-TOF) m/z: [M + H]
+ calculated
for C38H47N12O11S2
+ 911.2923, found 11.2831. Yellow solid.
Compound 2b (X: F) strategy B – AcGlyTrpCysĲb)-
HisValAlaNH2. 5.9 mg of peptide 2 was reacted with 2.34 mg of
4-fluoro-7-sulfobenzofurazan (b-F) in the presence of activated
molecular sieves and under an argon atmosphere. The reaction
mixture was stirred at room temperature for 12 h.
Yield (2b) after RP-HPLC purification: 31% (1.8 mg);
preparative HPLC tR = 15.462 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O11S2
+ 911.2923, found 911.2884.
Yellow solid.
Compound 2b 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
10.85 (d, 1H), 8.98 (s, br, 1H), 8.53 (d, 1H), 8.48 (d, 1H), 8.15–
8.10 (m, o, 3H), 7.83 (d, 1H), 7.70 (d, 1H), 7.60 (d, 1H), 7.43
(d, 1H), 7.40 (s, 1H), 7.34 (d, 1H), 7.27 (s, 1H), 7.18 (d, 1H),
7.07 (t, 1H), 7.00 (s, o, 1H), 6.99 (t, o, 1H), 4.69 (q, 1H), 4.59
(dt, 1H), 4.54 (q, 1H), 4.23 (m, 1H), 4.19 (dd, 1H), 3.77 (dd,
1H), 3.63 (dd, o, 1H), 3.59 (dd, o, 1H), 3.41 (dd, overlapping
with the water residual signal, 1H), 3.17 (dd, 1H), 3.12 (dd,
1H), 3.02 (dd, o, 1H), 2.97 (dd, o, 1H), 2.04 (m, 1H), 1.85 (s,
3H), 1.24 (d, 3H), 0.89 (d, 3H), 0.86 (d, 3H).
Compound 2c (X: F) strategy A – AcGly-
Ĳc)TrpCysHisValAlaNH2. 4.7 mg of peptide 2 was reacted with
1.09 mg of 4-fluoro-benzofurazan (c-F) in the presence of 3.35
μL of DIPEA (3 equiv.). The reaction mixture was stirred at
room temperature for 12 h.
Yield (2c) after RP-HPLC purification: 0.5%. Preparative
HPLC tR = 17.725 min; HRMS (ESI-TOF) m/z: [M + H]
+ calculated
for C38H47N12O8S
+ 831.3355, found 831.3327. White solid.
Compound 2c (X: F) strategy B – AcGly-
Ĳc)TrpCysHisValAlaNH2. 5.7 mg of peptide 2 was reacted with
1.36 mg of 4-fluoro-benzofurazan (c-F) in the presence of
activated molecular sieves and under an argon atmosphere.
The reaction mixture was stirred at room temperature for 12 h.
Yield (2c) after RP-HPLC purification: 30% (1.7 mg);
preparative HPLC tR = 17.670 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O8S
+ 831.3355, found 831.3279.
White solid.
Compound 2c (X: Cl) strategy A – AcGly-
Ĳc)TrpCysHisValAlaNH2. 4.7 mg of peptide 2 was reacted with
1.22 mg of 4-chloro-benzofurazan (c-Cl) in the presence of
3.35 μL of DIPEA (3 equiv.). The reaction mixture was stirred
at room temperature for 12 h.
Yield (2c) after RP-HPLC purification: 0%.
Compound 2c (X: Cl) strategy B – AcGly-
Ĳc)TrpCysHisValAlaNH2. 10.5 mg of peptide 2 was reacted
with 2.73 mg of 4-chloro-benzofurazan (c-Cl) in the presence
of activated molecular sieves and under an argon
atmosphere. The reaction mixture was stirred at room
temperature for 12 h.
Yield (2c) after RP-HPLC purification: 7% (∼0.2 mg);
preparative HPLC tR = 17.726 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O8S
+ 831.3355, found 831.3321
([M + H]+). White solid.
Compound 2c 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
10.87 (d, 1H), 8.96 (br, 1H), 8.55 (d, 1H), 8.44 (d, 1H), 8.17 (d,
br, 1H), 8.13 (t, 1H), 8.10 (d, 1H), 7.88 (d, 1H), 7.85 (d, 1H),
7.59 (d, 1H), 7.56 (d, 1H), 7.51 (d, 1H), 7.37 (br, 1H), 7.35 (d,
1H), 7.28 (s, 1H), 7.17 (d, 1H), 7.07 (t, 1H), 7.01 (s, 1H), 6.98
(t, 1H), 4.70 (q, 1H), 4.58–4.56 (m, o, 2H), 4.24 (m, 1H), 4.19
(dd, 1H), 3.78 (dd, 1H), 3.61 (m, o, 2H), 3.42 (dd, overlapping
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with the water residual signal), 3.16 (dd, o, 1H), 3.12 (dd,
1H), 3.01 (dd, 1H), 2.96 (dd, 1H), 2.04 (m, 1H), 1.85 (s, 3H),
1.24 (d, 3H), 0.89 (d, 3H), 0.86 (d, 3H).
Compound 2d (X: Br) strategy A – AcGly-
Ĳd)TrpCysHisValAlaNH2. 4.7 mg of peptide 2 was reacted with
1.58 mg of 5-bromo-benzofurazan (d-Br) in the presence of
3.35 μL of DIPEA (3 equiv.). The reaction mixture was stirred
at room temperature for 12 h.
Yield (2d-Br) after RP-HPLC purification: 0%.
Compound 2d (X: Br) strategy B – AcGly-
Ĳd)TrpCysHisValAlaNH2. 4.5 mg of peptide 2 was reacted with
1.51 mg of 5-bromo-benzofurazan (d-Br) in the presence of
activated molecular sieves and under an argon atmosphere.
The reaction mixture was stirred at room temperature for 12 h.
Yield (2d) after RP-HPLC purification: 24% (1.1 mg);
preparative HPLC tR = 17.838 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O8S
+ 831.3355, found 831.3337
([M + H]+). White solid.
Compound 2d (X: Cl) strategy A – AcGly-
Ĳd)TrpCysHisValAlaNH2. 4.7 mg of peptide 2 was reacted with
1.22 mg of 5-chloro-benzofurazan (d-Cl) in the presence of
3.35 μL of DIPEA (3 equiv.). The reaction mixture was stirred
at room temperature for 12 h.
Yield (2d-Cl) after RP-HPLC purification: 0%.
Compound 2d (X: Cl) strategy B – AcGly-
Ĳd)TrpCysHisValAlaNH2. 6.5 mg of peptide 2 was reacted with
1.71 mg of 5-chloro-benzofurazan (d-Cl) in the presence of
activated molecular sieves and under an argon atmosphere.
The reaction mixture was stirred at room temperature for 12 h.
Yield (2d) after RP-HPLC purification: 5% (∼0.3 mg);
preparative HPLC tR = 17.944 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C38H47N12O8S
+ 831.3355, found 831.3344
([M + H]+). White solid.
Compound 2d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
10.87 (s, 1H), 8.97 (br, 1H), 8.57 (br, 1H), 8.52 (d, 1H), 8.17–
8.11 (m, o, 3H), 8.01 (d, 1H), 7.87 (s, 1H), 7.83 (d, 1H), 7.61
(d, 1H), 7.46 (d, 1H), 7.36 (d, 1H), 7.27 (br, 1H), 7.17 (s, 1H),
7.08 (t, 1H), 7.02–6.99 (m, o, 2H), 4.70 (br, 1H), 4.63–4.62 (m,
o, 2H), 4.26 (m, 1H), 4.19 (br, 1H), 3.78 (dd, 1H), 3.61 (dd,
1H), 3.49 (dd, overlapping with the water residual signal),
3.18 (dd, 1H), 3.13 (br, o), 3.01 (br, o), 2.97 (dd, o, 1H), 2.05
(m, 1H), 1.85 (s, 3H), 1.25 (d, 3H), 0.90 (d, 3H), 0.87 (d, 3H).
Compound 3d (X: Br) strategy B – AcCys-
Ĳd)GlyMetValAlaNH2. 4.9 mg of peptide 3 was reacted with
2.24 mg of 5-bromo-benzofurazan (d-Br) in the presence of
activated molecular sieves and under an argon atmosphere.
The reaction mixture was stirred at room temperature for 12 h.
Yield (3d) after RP-HPLC purification: 49% (2.4 mg);
preparative HPLC tR = 18.577 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C26H39N8O7S2
+ 639.2378, found 639.2380.
Compound 3d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.61 (t, 1H), 8.49 (d, 1H), 8.00 (d, 1H), 7.97 (d, 1H), 7.91–7.88
(m, o, 3H), 7.48 (dd, 1H), 7.29 (s, 1H), 7.01 (s, 1H), 4.65 (dt,
1H), 4.46 (dt, 1H), 4.23 (m, 1H), 4.17 (dd, 1H), 3.78 (ABX
system, 2H), 3.53 (dd, 1H), 3.33 (dd, overlapping with the
residual water signal), 2.47 (m, overlapping with solvent),
2.07 (s, 3H), 2.03 (m, 2H), 1.95 (m, 1H), 1.91 (s, 3H), 1.83 (m,
1H), 1.23 (d, 3H), 0.88 (d, 3H), 0.86 (d, 3H).
Compound 4d (X: Br) strategy B – AcCys-
Ĳd)GlyTrpValAlaNH2. 6.2 mg of peptide 4 was reacted with 2.57
mg of 5-bromo-benzofurazan (d-Br) in the presence of activated
molecular sieves and under an argon atmosphere. The reaction
mixture was stirred at room temperature for 12 h.
Yield (4d) after RP-HPLC purification: 29% (1.8 mg);
preparative HPLC tR = 19.847 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C32H40N9O7S
+ 694.2766, found 694.2780.
White solid.
Compound 4d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
10.81 (d, 1H), 8.53 (t, 1H), 8.43 (d, 1H), 8.04 (d, 1H), 8.01 (d,
1H), 7.97 (d, 1H), 7.91 (d, 1H), 7.87 (s, 1H), 7.62 (d, 1H), 7.45
(dd, 1H), 7.33 (d, 1H), 7.29 (s, 1H), 7.15 (d, 1H), 7.07 (t, 1H),
7.02 (s, 1H), 6.99 (t, 1H), 4.67–4.66 (m.o, 2H), 4.26 (m, 1H),
4.19 (dd, 1H), 3.82 (dd, 1H), 3.64 (dd, 1H), 3.48 (dd, 1H), 3.29
(dd, 1H), 3.19 (dd, 1H), 2.98 (dd, 1H), 2.05 (m, 1H), 1.89 (s,
3H), 1.25 (d, 3H), 0.89 (d, 3H), 0.87 (d, 3H).
13C-NMR δ, ppm, (from HSQC/HMBC, 150 MHz, DMSO-
d6, 298 K): 174.8, 171.1, 171.0, 170.8, 170.5, 169.6, 149.9,
148.6, 144.1, 136.9, 134.2, 127.7, 124.3, 121.4, 119.1, 118.7,
116.3, 111.8, 110.3, 107.9, 58.4, 54.0, 51.8, 48.7, 42.7, 33.7,
31.1, 28.3, 23.2, 19.6, 18.9, 18.8.
Compound 5d (X: Br) strategy B – AcCys-
Ĳd)GlyThrValAlaNH2. 5.7 mg of peptide 5 was reacted with 2.78
mg of 5-bromo-benzofurazan (d-Br) in the presence of activated
molecular sieves and under an argon atmosphere. The reaction
mixture was stirred at room temperature for 12 h.
Yield (5d) after RP-HPLC purification: 35% (2.0 mg);
preparative HPLC tR = 16.782 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C25H37N8O8S
+ 609.2450, found m/z
609.2418 ([M+H]+). White solid.
Compound 5d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.63 (t, 1H), 8.50 (d, 1H), 8.00 (d, 1H), 7.94 (d, 1H), 7.90 (s,
1H), 7.78 (d, o, 1H), 7.77 (d, o, 1H), 7.48 (dd, 1H), 7.22 (s,
1H), 7.00 (s, 1H), 5.01 (d, 1H), 4.68 (dt, 1H), 4.37 (dd, 1H),
4.21 (m, o, 2H), 4.04 (m, 1H), 3.88 (dd, 1H), 3.82 (dd, 1H),
3.52 (dd, 1H), 3.33 (m, overlapping with the water residual
signal), 2.06 (m, 1H), 1.91 (s, 3H), 1.23 (d, 3H), 1.07 (d, 3H),
0.90 (d, 3H), 0.87 (d, 3H).
Compound 6d (X: Br) strategy B – AcCys-
Ĳd)GlyHisValAlaNH2. 5.9 mg of peptide 6 was reacted with 2.68
mg of 5-bromo-benzofurazan (d-Br) in the presence of activated
molecular sieves and under an argon atmosphere. The reaction
mixture was stirred at room temperature for 12 h.
Yield (6d) after RP-HPLC purification: 30% (1.8 mg);
preparative HPLC tR = 29.905 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C27H37N10O7S
+ 645.2562, found 645.2568.
White solid.
Compound 6d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.94 (br, exchange), 8.60 (t, 1H), 8.49 (d, 1H), 8.17 (br, 1H),
8.15 (d, 1H), 8.00 (d, 1H), 7.92 (d, 1H), 7.87 (s, 1H), 7.48 (dd,
1H), 7.33 (br, exchange), 7.27 (s, 1H), 7.02 (s, 1H), 4.70 (br, o,
1H), 4.65 (dt, 1H), 4.24 (m, 1H), 4.17 (dd, 1H), 3.80 (dd, 1H),
3.75 (dd, 1H), 3.53 (dd, 1H), 3.33 (m, overlapping with the
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water residual signal), 3.09 (br, 1H), 2.98 (br, 1H), 2.05 (m,
1H), 1.91 (s, 3H), 1.25 (d, 3H), 0.90 (d, 3H), 0.87 (d, 3H).
Compound 7d (X: Br) strategy B – AcCys-
Ĳd)GlyLysValAlaNH2. 7.0 mg of peptide 7 was reacted with 3.23
mg of 5-bromo-benzofurazan (d-Br) in the presence of activated
molecular sieves and under an argon atmosphere. The reaction
mixture was stirred at room temperature for 12 h.
Yield (7d) after RP-HPLC purification: 45% (3.1 mg);
preparative HPLC tR = 15.055 min; HRMS (ESI-TOF) m/z: [M +
H]+ calculated for C27H42N9O7S
+ 636.2943, found 636.2976.
White solid.
Compound 7d 1H-NMR δ, ppm (600 MHz, DMSO-d6, 298 K).
8.58 (t, 1H), 8.49 (d, 1H), 8.01 (d, 1H), 7.95 (d, 1H), 7.89–7.87
(m, o, 3H), 7.64 (br, exchange), 7.48 (dd, 1H), 7.32 (s, 1H),
7.02 (s, 1H), 4.66 (dt, 1H), 4.38 (dt, 1H), 4.22 (m, 1H), 4.17
(dd, 1H), 3.78 (ABX system, 2H), 3.50 (dd, 1H), 3.32
(overlapping with the water residual signal), 2.79 (m, 2H),
2.04 (m, 1H), 1.91 (s, 3H), 1.71–1.55 (m, o, 5H), 1.32 (m, 1H),
1.23 (d, 3H), 0.88 (d, 3H), 0.86 (d, 3H).
Compound 7b (X: Cl) strategy B – AcCys-
Ĳb)GlyLysValAlaNH2. 9.6 mg of peptide 7 was reacted with 5.30
mg of 5-chloro-7-sulfobenzofurazan (b-Cl) in the presence of
activated molecular sieves and under an argon atmosphere.
The reaction mixture was stirred at room temperature for 12 h.
Yield (7b) after RP-HPLC purification: 42% (4.0. mg);
preparative HPLC tR = 12.248 min (co-eluted with the substrate
employed b-Cl); HRMS (ESI-TOF) m/z: [M + H]+ calculated for
C27H42N9O10S2
+ 716.2503, found 716.2564. Yellow solid.
Conclusion
In conclusion, a clean, mild and efficient procedure to
selectively introduce benzofurazan moieties into peptide
sequences via S-conjugation was developed. It relies on the
moderate catalytic activity of activated molecular sieves to
promote the reaction.
We showed that our protocol can be successfully applied
to a number of different benzofurazan halogenides, even
those lacking activating groups. Hydrophilic fluorescent
peptide-based probes were prepared, proving the potential
and the reliability of the developed synthetic method.
As a final remark, the excellent chemoselectivity for
cysteine over lysine provided by the mild catalytic conditions
paves the way for dual-labelled peptides, as S-alkylated
peptides can be subjected to sequential N-alkylation to add
another functional group. The developed protocol can be
potentially used to synthesize multi-functionalized peptides
on a scale allowing applications beyond analytical purposes.
This matter certainly deserves further studies, considering
the ease of handling of the reaction mixture and a simple
final work up that characterizes the modification of peptide
molecules under the reported reaction conditions.
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